Narasimhan
Biotech

Novartis CEO keeps faith in Avidity despite $1.9B hit from fail

Vas Narasimhan insisted the phase 3 fail for del-desiran is just a “bump” in the pharma’s wider plans for the drug, despite costing $1.9 billion.
James Waldron Oct 27, 2026 3:48am
Incyte

ESMO: Incyte claims ‘neck and neck’ KRAS G12D race with RevMed

Oct 26, 2026 9:45am
Weight loss pills Obesity treatment

Why Corxel picked SPAC route to take obesity biotech public

Oct 27, 2026 6:00am
digital dollar with tech background

Anthropic details drug R&D ambitions, risks in IPO filing

Oct 26, 2026 2:00pm
ribbon colors awareness

BMS joins 3-year collab to boost cancer trial participation

Oct 27, 2026 5:00am
GSK booth at ASCO 2026

GSK’s B7-H3 ADC drives 67% cancer risk reduction in phase 3

Oct 27, 2026 3:28am
More News

Boehringer, Microsoft explore digital twins for clinical trials

Oct 26, 2026 2:49pm

Lycia leaps onto Nasdaq with $318M IPO as Windward eyes debut

Oct 26, 2026 10:00am

BioNTech sees limited ADC benefit as ph. 3 shows modest efficacy

Oct 26, 2026 8:39am

ESMO: Genmab's ph. 3 win for Rina-S, fresh data on Merus prize

Oct 26, 2026 7:00am